Content by NanoPac, Inc. Learn how Tulsa-based assistive technology company NanoPac helps people struggling with low vision ...

A new study suggests hormone replacement therapy, or HRT, may help protect vision during menopause. Researchers found women using HRT had an 8% lower glaucoma risk than those who did not use it. The ...

July 9 (Reuters) - Bausch + Lomb said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial of replicating visual function improvements observed in a smaller study. The ...

Glaucoma is the leading cause of irreversible visual impairment worldwide. Because the disease often progresses without ...

Dr Ray O’Connor takes a look at recent clinical papers on ophthalmology, in particular the current and future burden of ...

Instead of pursuing the eye drop further in glaucoma, Bausch + Lomb will focus on developing a sustained-release implant ...

Glaucoma is a group of eye diseases that damage the optic nerve, which carries visual information from the eye to the brain.

Eyecare company Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to ...

Glaucoma can silently damage vision but everyday habits may influence its progression. Learn seven common mistakes patients ...

From memorable patient encounters to emerging therapies, OT talks with practitioners about opportunities and challenges in ...

I heard Wayne had to give up driving because he is blind from glaucoma, but I saw him at the cafe reading a newspaper. I’m struggling to make sense of that: what is glaucoma?” ...

Bausch + Lomb has abandoned its next great hope in glaucoma after the eye drops flunked a phase 2 study. The eye health company had been evaluating the alpha-2B agonist, dubbed BL1107, in a mid-stage ...